The Great Debate: CAR-T-Cell Therapy Versus Bispecific Antibodies in B-Cell Lymphoma
Cancers · 05.08.2026 · 18 (15) · 2513
DOI: 10.3390/cancers18152513 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 05.08.2026. Verfasst von Massimo Martino und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropol…. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The treatment paradigm for relapsed/refractory (R/R) large B-cell lymphoma (LBCL) has undergone significant change with the advent of CD19-directed chimeric antigen receptor T-cell (CAR-T) therapies and CD20 × CD3 bispecific antibodies (BsAbs). Although both approaches have shown high response rates in single-arm studies, the absence of prospective randomized head-to-head comparisons has resulted in true clinical equipoise.
Methods
A narrative synthesis was conducted, incorporating pivotal and updated phase 2 and 3 trial data, real-world evidence, and published meta-analyses.
Results
In the second-line setting, CAR-T therapy demonstrates superior event-free survival, progression-free survival, and overall survival compared to standard-of-care chemo-transplant regimens. In the third-line setting, a pooled meta-analysis indicates significantly higher complete response rates for CAR-T compared with BsAbs, as well as superior 12-month progression-free survival. BsAbs provide immediate availability, greater accessibility, more favorable neurotoxicity profiles, and are feasible for frail or elderly patients. Real-world data show that BsAb complete response rates are consistently lower than those observed in clinical trials, whereas CAR-T real-world effectiveness closely aligns with pivotal trial outcomes. Emerging phase 3 data on fixed-duration and monotherapy bispecific regimens suggest that a genuine, if less mature, curative fraction may also be achievable among BsAb-treated complete responders.
Conclusions
CAR-T therapy remains the standard of care for fit, eligible patients with R/R LBCL in second- and third-line settings with curative intent, providing superior depth and durability of response and a growing potential for long-term cure. BsAbs constitute a critical therapeutic alternative for patients ineligible for CAR-T, those with rapidly progressive disease, frail or elderly individuals, and as bridging strategies. A patient-centered, scenario-specific clinical decision framework is recommended.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", 89133 Reggio Calabria, Italy.
ORCID-Profile: Massimo Martino, Martina Pitea, Gaetana Porto
Zitieren
APA
Martino, M., Marafioti, V., Pitea, M., Porto, G., Policastro, G., Canale, F. A., Naso, V., & Alati, C. (2026). The Great Debate: CAR-T-Cell Therapy Versus Bispecific Antibodies in B-Cell Lymphoma. Cancers, 18(15), 2513. https://doi.org/10.3390/cancers18152513
Vancouver
Martino M, Marafioti V, Pitea M, Porto G, Policastro G, Canale FA, et al. The Great Debate: CAR-T-Cell Therapy Versus Bispecific Antibodies in B-Cell Lymphoma. Cancers. 2026;18(15):2513. doi:10.3390/cancers18152513
BibTeX
@article{Martino2026,
author = {Martino, Massimo and Marafioti, Violetta and Pitea, Martina and Porto, Gaetana and Policastro, Giorgia and Canale, Filippo Antonio and Naso, Virginia and Alati, Caterina},
title = {The Great Debate: CAR-T-Cell Therapy Versus Bispecific Antibodies in B-Cell Lymphoma},
journal = {Cancers},
year = {2026},
volume = {18},
number = {15},
pages = {2513},
doi = {10.3390/cancers18152513}
}
EUVIMED